In this video, Dr. Naresh Kumar, Consultant Diabetologist from Tamil Nadu, presents a real-world case of a 24-year-old male student with fatigue and polyuria, diagnosed with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) risk.

The patient was initiated on a triple fixed-dose combination (FDC) of vildagliptin, dapagliflozin, and metformin, leading to rapid and sustained clinical improvements.

Within just 4 weeks, fasting and postprandial blood glucose levels were effectively controlled. Over 6 months, HbA1c dropped significantly from 9.3% to 6.5%, reflecting excellent glycemic management. Notably, homocysteine levels normalized, reducing cardiovascular risk, while the patient reported marked improvement in energy levels, overall well-being, and quality of life.

This case underscores the value of early initiation of vildagliptin–dapagliflozin–metformin FDC in young patients with uncontrolled T2DM and elevated CV risk, highlighting its efficacy, safety, and potential to improve both metabolic and cardiovascular outcomes.